Drug Patent Watch

FEBRUARY 12, 2024

Annual Drug Patent Expirations for FLONASE+SENSIMIST+ALLERGY+RELIEF Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. It is available from two suppliers.

Allergies 59

Allergies Drugs Marketing 59

Fierce Pharma

SEPTEMBER 5, 2023

billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. After lackluster sales dampened the initial enthusiasm that came with a $2.1

Allergies 72

Allergies Drugs Sales 72

pharmaphorum

SEPTEMBER 4, 2023

Nestle sells underperforming peanut allergy drug Phil.Taylor Mon, 04/09/2023 - 10:49 Bookmark this

Allergies 59

Allergies Drugs 59

Outsourcing Pharma

SEPTEMBER 16, 2021

The US agency has given the go-ahead to Cour Pharmaceuticals to evaluate the safety and efficacy of CNP-201, a drug intended to treat peanut allergies.

Allergies 105

Allergies FDA Approval Drugs Regulation 105

Medical Xpress

NOVEMBER 28, 2022

Philip Li from the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has pioneered a new nurse-led penicillin allergy triage and testing strategy—the Hong Kong Drug Allergy Delabelling Initiative (HK-DADI), and demonstrated its effectiveness and safety compared to traditional allergy testing.

Allergies 98

Allergies Nurses Medicine Drugs 98

Bio Pharma Dive

JULY 18, 2022

The food giant will pay French company Enterome about $40 million to join in the development of an inflammatory bowel disease drug as well as other food allergy treatments.

Allergies 254

Allergies Drugs Development 254

NY Times

DECEMBER 11, 2020

British health officials recommended that people with severe allergy reactions not be given the vaccine. Such reactions to vaccines are rare, even in people who have allergies to food or bee stings.

Allergies 140

Allergies Vaccination Vaccine Clinical Trials 140

Medical Xpress

APRIL 10, 2023

Spring allergies can be brutal, and many—but by no means all—sufferers reach for synthetic medications to combat their symptoms.

Allergies 75

Allergies Drugs 75

Drug Discovery World

JUNE 26, 2023

IgGenix has made advances towards a peanut allergy therapeutic based on IgG4 monoclonal antibodies. The company’s research data was presented during the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, in Hamburg, Germany. The post Could a monoclonal antibody treat peanut allergy?

Allergies 52

Allergies Antibody In-Vivo In-Vitro 52

Drug Patent Watch

AUGUST 24, 2021

Annual Drug Patent Expirations for ASTEPRO+ALLERGY Astepro Allergy is a drug marketed by Bayer Hlthcare and is included in one NDA. The generic ingredient in ASTEPRO ALLERGY is azelastine hydrochloride.….

Allergies 52

Allergies Drugs Marketing 52

Drug Patent Watch

AUGUST 14, 2021

Annual Drug Patent Expirations for ASTEPRO+ALLERGY Astepro Allergy is a drug marketed by Bayer Hlthcare and is included in one NDA. The generic ingredient in ASTEPRO ALLERGY is azelastine hydrochloride.….

Allergies 52

Allergies Drugs Marketing 52

XTalks

JANUARY 17, 2023

The US Food and Drug Administration (FDA) has added sesame to its list of major allergens, making it easier for people with sesame allergies to safely consume packaged food without fear of an allergic reaction. Related: Top 3 Allergy Friendly Food Brands. percent of children and adults in the US are allergic to sesame.

Allergies 98

Allergies Packaging Packaging Containment 98

BioTech 365

APRIL 27, 2021

Allergy Treatment Market Report 2021: Analysis By Allergy Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergies, and Other Allergies); Treatment (Anti-Allergy Drugs, and Immunotherapy) – ResearchAndMarkets.com Allergy Treatment Market Report 2021: Analysis By Allergy Type (Eye Allergy, Rhinitis, Asthma, … Continue reading → (..)

Allergies 40

Allergies Marketing Drugs 40

Medical Xpress

FEBRUARY 16, 2023

What if an over-the-counter allergy medicine could help halt and even reverse multiple sclerosis? And if it did, could patients return to their full capacity? Those were some of the questions first posed in 2013 after a landmark discovery by UC San Francisco neuroscientist Jonah Chan, Ph.D., and physician-scientist Ari Green, MD.

Allergies 75

Allergies Scientist Medicine Drugs 75

Drug Patent Watch

AUGUST 24, 2021

Annual Drug Patent Expirations for CHILDREN%27S+ASTEPRO+ALLERGY For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com.

Allergies 52

Allergies Drugs 52

Drug Patent Watch

NOVEMBER 25, 2021

Annual Drug Patent Expirations for CHILDREN%27S+ALLEGRA+ALLERGY For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com.

Allergies 52

Allergies Drugs 52

Drug Patent Watch

AUGUST 14, 2021

Annual Drug Patent Expirations for CHILDREN%27S+ASTEPRO+ALLERGY For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com.

Allergies 52

Allergies Drugs 52

Drug Patent Watch

AUGUST 2, 2021

Annual Drug Patent Expirations for FLONASE+SENSIMIST+ALLERGY+RELIEF Flonase Sensimist Allergy Relief is a drug marketed by Glaxosmithkline Cons and is included in one NDA. It is available from one supplier.

Allergies 52

Allergies Drugs Marketing 52

Drug Discovery World

OCTOBER 13, 2022

New research has shown that standard cat allergy treatment can be enhanced to make it more effective and faster acting, and the benefits last for a year after treatment ends. The findings of the study, supported by the National Institutes of Health, were published in the Journal of Allergy and Clinical Immunology. .

Allergies 52

Allergies Gene Antibody Trials 52

Pharma Times

DECEMBER 21, 2020

Drug becomes first treatment for peanut allergy in the EU

Allergies 124

Allergies Drugs 124

Drug Patent Watch

DECEMBER 24, 2020

Annual Drug Patent Expirations for ALLEGRA-D+24+HOUR+ALLERGY+AND+CONGESTION Allegra-d 24 Hour Allergy And Congestion is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from….

Allergies 52

Allergies Drugs Marketing 52

BioTech 365

JULY 22, 2021

Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit Scientific Data Outlines the Role of the Oral Mucosa in the Delivery of Peanut Allergy Immunotherapy NEW YORK, July 22, 2021 (GLOBE … Continue reading →

Allergies 40

Allergies Drugs 40

BioTech 365

AUGUST 24, 2021

Grass Pollen Allergy Drugs In Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com Grass Pollen Allergy Drugs In Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Grass Pollen Allergy (Immunology) – Drugs In Development, 2021” report has been added (..)

Allergies 40

Allergies Development Drugs 40

pharmaphorum

DECEMBER 10, 2020

Moncef Slaoui, co-head of the US government’s Operation Warp Speed COVID-19 vaccine programme, made the comments after the UK drugs regulator advised those with severe allergies to avoid the vaccine. The post Coronavirus vaccine may have allergy warning in US, says expert appeared first on.

Allergies 103

Allergies Vaccination Vaccine Regulation 103

pharmaphorum

OCTOBER 27, 2021

AIT involves the administration of controlled, low doses of allergens under the tongue or by subcutaneous injection in people with allergies, with the aim of desensitising the immune system to them and prevent allergic reactions. ” The post Allergy specialist Stallergenes taps Aptar for digital delivery appeared first on.

Allergies 64

Allergies Drug Delivery Development Marketing 64

Druggist

APRIL 20, 2021

Today I will explore a different use of montelukast and answer the main question: can you use montelukast for allergies? Can you use montelukast for allergies? Classified as a leukotriene receptor antagonist (LTRA), montelukast has a distinct mechanism of action compared to other drugs, including those used to treat asthma.

Allergies 52

Allergies Licensing Licensing Drugs 52

BioPharma Reporter

MAY 20, 2022

The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

Allergies 105

Allergies Drugs Development Drug Delivery 105

XTalks

SEPTEMBER 28, 2023

In most cases, commercials are regulated to ensure they provide accurate information, include the benefits and risks of the drugs and encourage viewers to talk to their healthcare providers about the medication. The report included a roundup of the top ten TV ad debuts this year, with pharma drugs clinching the top three spots.

Drugs 105

Drugs Allergies Branding FDA Approval 105

Medical Xpress

DECEMBER 2, 2022

Cough medicines containing the chemical pholcodine should be banned due to the risk of potentially deadly allergic reactions in people under general anaesthetic, the European Union's drug regulator said Friday.

Allergies 96

Allergies Containment Regulation Medicine 96

The Pharma Data

MARCH 15, 2022

Itchy allergy eyes affect an estimated 40% of Americans 1. Allergan, an AbbVie (NYSE: ABBV) company, today announced that LASTACAFT ® (alcaftadine ophthalmic solution 0.25%) is now available without a prescription for the estimated 40% of Americans 1 who live with ocular allergies. 2 Following the recent U.S.

Allergies 52

Allergies Production Containment Medicine 52

Drug Discovery World

JUNE 30, 2023

Whether it be a monoclonal antibody to treat peanut allergy, or using artificial intelligence (AI) to identify influenza drug targets, each discovery reflects the level of scientific innovation and diversity of approaches being employed in drug development today. The top stories: Could a monoclonal antibody treat peanut allergy?

Allergies 52

Allergies Drugs Antibody Regulation 52

pharmaphorum

AUGUST 5, 2020

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end. The rationale behind Viaskin Peanut is to expose people with peanut allergy to small, rising amounts of peanut protein – which acts as an allergen – to encourage the immune system to develop tolerance over time.

Allergies 52

Allergies Production Clinical Trials Clinical Trials 52

BioTech 365

DECEMBER 15, 2021

Global Rx-to-OTC Switches Market Landscape 2021-2031 – Allergy & Respiratory Drugs Anticipated to Gain a Revenue Share of More Than 25% – ResearchAndMarkets.com Global Rx-to-OTC Switches Market Landscape 2021-2031 – Allergy & Respiratory Drugs Anticipated to Gain a Revenue Share … Continue reading →

Allergies 40

Allergies Marketing Drugs 40

The Pharma Data

JANUARY 7, 2021

This clearance is a pivotal regulatory milestone that further supports Camallergy’s leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy,” said Sherden Timmins, Chief Technology Officer. 8, 2021 07:00 UTC. About Camallergy.

Allergies 52

Allergies Manufacturing Production Clinical Trials 52

Medical Xpress

MAY 12, 2023

Food and Drug Administration voted Thursday to recommend approval of Neffy, the first epinephrine nasal spray for severe allergic reactions. Outside advisors for the U.S.

Allergies 105

Allergies Drugs 105

BioTech 365

JANUARY 7, 2021

Camallergy’s UK Based Manufacturing Facility Receives cGMP Licences for Peanut Allergy Treatment Camallergy’s UK Based Manufacturing Facility Receives cGMP Licences for Peanut Allergy Treatment -Only European cGMP-certified manufacturing facility for peanut allergy oral immunotherapy -Facility to supply drug product for … Continue reading → (..)

Allergies 52

Allergies Manufacturing Production Drugs 52

BioSpace

SEPTEMBER 19, 2023

Though it received backing from the Pulmonary-Allergy Drugs Advisory Committee in May, the FDA on Tuesday rejected ARS Pharmaceuticals’ neffy as a nasal spray for allergic reactions.

Allergies 119

Allergies Drugs 119